PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Product profile • REVLIMID • VIDAZA • Dacogen • Glivec/Gleevec PART 04: Market research methodology • Research methodology • Economic indicators PART 05: Introduction • Key market highlights PART 06: Disease overview • Understanding the disease • Risk factors • Signs and symptoms • Pathophysiology • Types • Diagnosis • Epidemiology • Treatment PART 07: Pipeline portfolio • Information on pipeline candidates PART 08: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by drug class • Alkylating agents • Cytotoxic antibiotics • Topoisomerase inhibitors • Others PART 10: Market segmentation by route of administration • Oral • Parenteral PART 11: Geographical Segmentation • Myelodysplastic syndrome market in EMEA • Myelodysplastic syndrome market in APAC PART 12: Market drivers • Rise in aging population • Unmet medical needs • Use of diagnostic tools PART 13: Impact of drivers PART 14: Market challenges • Use of off-label drugs • Adverse effects of drugs • High cost of drugs PART 15: Impact of drivers and challenges PART 16: Market trends • Rise in public awareness • Patient assistance programs • Increase in R&D • Intense competition PART 17: Vendor landscape • Competitive scenario • Market share analysis 2014 • Other prominent vendors PART 18: Key vendor analysis • Celgene • Novartis • Otsuka Holdings PART 19: Appendix • List of abbreviations PART 20: Explore Technavio LOE Exhibit 01: Product offerings Exhibit 02: Myelodysplastic syndrome: Risk factors Exhibit 03: Myelodysplastic syndrome: Signs and symptoms Exhibit 04: History of myelodysplastic syndrome classification system Exhibit 05: FAB classification system: Types of myelodysplastic syndrome Exhibit 06: WHO classification system: Types of myelodysplastic syndrome Exhibit 07: IPSS classification: Factors and score Exhibit 08: IPSS-R classification: Cytogenetic score Exhibit 09: IPSS-R classification: Score values Exhibit 10: IPSS-R classification: Risk categories and scores Exhibit 11: Diagnostic tests for myelodysplastic syndrome Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years) Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011 Exhibit 14: Treatment options for myelodysplastic syndrome Exhibit 15: Chemotherapeutic agents Exhibit 16: Immunotherapy drugs Exhibit 17: Supportive therapy for myelodysplastic syndrome Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome Exhibit 19: Myelodysplastic syndrome: Drug pipeline Exhibit 20: Global myelodysplastic syndrome market ($ millions) Exhibit 21: Five forces analysis Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014 Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions) Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions) Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions) Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions) Exhibit 29: Impact of drivers Exhibit 30: Impact of drivers and challenges Exhibit 31: Ranking of leading companies Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions) Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions) Exhibit 34: Celgene: Key takeaways Exhibit 35: Otsuka Holdings: Key takeaways Exhibit 36: Novartis: Key takeaways Exhibit 37: Celgene: Product segmentation by revenue 2014 Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014 Exhibit 39: Celgene: Geographical segmentation by revenue 2014 Exhibit 40: Novartis: Business segmentation by revenue 2014 Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 42: Novartis: Geographical segmentation by revenue 2014 Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014 Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014

Celgene, Novartis, Otsuka, Acceleron Pharma, Amgen, Astellas, Astex , Actinium Pharmaceuticals, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Eli-lilly, Gamida Cell , GlaxoSmithKline, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Onconova Therapeutics, Strategia Therapeutics, Sumitomo Dainippon Pharma , Sunesis Pharmaceuticals, Targazyme, TetraLogic Pharmaceuticals.